• KOL
    • KOLs Community
    • Mycosis
    • Mycosis Fungoides
    • Robin J Russell‐jones
    • Robin J Russell‐Jones

      Robin J Russell‐Jones

      St John's Institute of Dermatology London UK | Melanoma Group, Skin Tumour Unit, St John’s Institute of Dermatology, St Thomas’ Hospital, London, UK | St John’s Institute of ...

       

       

      KOL Resume for Robin J Russell‐Jones

      Year
      2015

      St John's Institute of Dermatology London UK

      2009

      Melanoma Group, Skin Tumour Unit, St John’s Institute of Dermatology, St Thomas’ Hospital, London, UK

      St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Trust, London SE1 7EH, U.K.

      2008

      Skin Tumour Unit

      St John’s Institute of Dermatology, St Thomas’ Hospital, Lambeth Palace Road, London SE1 7EH, U.K.

      2007

      Skin Tumour Unit and *Dermatopathology Laboratory, St John’s Institute of Dermatology, St Thomas’ Hospital, King’s College London, U.K

      2006

      From the Skin Tumor Unit

      2005

      Skin Tumour Unit, St Thomas' Hospital, London SE1 7EH, UK

      Department of Dermatopathology, St John’s Institute of Dermatology

      2004

      Skin Tumor Unit, St John's Institute of Dermatology, St Thomas' Hospital, London, United Kingdom

      Department of Dermatology, Ealing Hospital, Southall, UK

      St John's Institute of Dermatology, St Thomas Hospital, London SE1 7EH

      2003

      Department of Dermatology, Ealing Hospital, London, and

      Skin Tumour Unit, St John's Institute of Dermatology, St Thomas' Hospital, London, UK

      2002

      Skin Tumour Unit and †Department of Diagnostic Dermatopathology, St John's Institute of Dermatology, St Thomas' Hospital, London SE1 7EH, U.K. Departments of *Plastic Surgery and ‡Nuclear Medicine, St Thomas' Hospital, London SE1 7EH, U.K.

      Affiliations of the group of preparers of this report: MCP Hahnemann University, Philadelphiaa; University of Turinb; University of Zurichc; University of Texas—M. D. Anderson Cancer Center, Houstond; Yale University, New Havene; University of Paris XIII, Bobignyf; Duke University, Durhamg; Mayo Clinic, Rochesterh; St John's Institute of Dermatology, Londoni; Hamamatsu Universityj; and Leiden University Medical Center.k

      Department of Dermatology, Ealing Hospital NHS Trust, Middlesex, United Kingdom

      2001

      From the Skin Tumour Unit, Department of Dermatopathology, St John’s Institute of Dermatology; Departments of Plastic Surgery and Nuclear Medicine, Guys & St Thomas’ Hospital; and Department of Dermatology, King’s College Hospital, London, United Kingdom.

      Skin Tumour Unit, St John's Institute of Dermatology, St Thomas' Hospital, London SE1 7EH, UK

      Department of Dermatology, 
Ealing Hospital NHS Trust, 
Uxbridge Road, 
Middlesex UB1 3HW, U.K

      2000

      Skin Tumour Unit, St John's Institute of Dermatology, St Thomas' Hospital, London SE1 7EH, UK.

      1999

      Skin Tumour Unit, St John’s Institute of Dermatology, St Thomas’ Hospital, London, UK

      St. John's Institute of Dermatology, London,

      Departments of Dermatology

      1998

      Skin Tumour Unit, St John's Institute of Dermatology, St Thomas' Hospital, London, U.K.

      Department of Dermatology, Ealing Hospital NHS Trust, Southall, Middlesex, UB1 3HW, UK

      1997

      Department of Dermatology, Ealing Hospital NHS Trust, Southall, Middlesex, England

      St John's Institute of Dermatology, London, U.K

      1988

      St John's, Hospital for Diseases of the Skin, 5 Lisle Street, London WC2H 7BJ, UK

       

       

      Robin J Russell‐Jones: Influence Statistics

      Sample of concepts for which Robin J Russell‐Jones is among the top experts in the world.
      Concept World rank
      pcbcl presence #1
      8methoxypsoralentreated cells #1
      limited poikilodermatous patches #1
      immunoparesis immunosuppression #1
      active ulceration improvement #1
      subjects publication biomarkers #1
      interferon uk guidelines #1
      syringotropic form #1
      nodal systemic disease #1
      sln status subjects #1
      recording sites involvement #1
      ecp cytokine production #1
      tc1 cytokines #1
      mycosis fungoides region #1
      3 cases cd56 #1
      ctcl slha #1
      male sézary #1
      dermal mucinosis association #1
      experience lm #1
      numerous vacuolated spaces #1
      systemic bcell lymphoma #1
      topical imiquimod immunotherapy #1
      single cutaneous tumor #1
      cd30 lymphomatoid papulosis #1
      surgical excision imiquimod #1
      organbased classification #1
      cd56 cytotoxic immunophenotype #1
      real eortc #1
      segmental unilateral area #1
      classification hematopoietic #1
      ctcl association #1
      12 47 years #1
      literature ecp #1
      lip sézary #1
      result ground substance #1
      types mycosis fungoides #1
      mbr bcl2 #1
      chromosome 36 pcbcl #1
      syndrome livedoid #1
      literature syringotropic ctcl #1
      primary sezary #1
      markers bcc #1
      systemic b‐cell lymphoma #1

       

      Prominent publications by Robin J Russell‐Jones

      KOL-Index: 16208

      BACKGROUND: BCL2 is upregulated in nodal and extranodal B-cell non-Hodgkin's lymphomas, with a consequent antiapoptotic effect. However, loss of BCL2 has also been noted in some malignancies, suggesting a different molecular pathogenesis.

      OBJECTIVES: To investigate genomic and protein expression status of BCL2 and to compare the results with that of JUNB in primary cutaneous lymphomas (PCLs).

      METHODS: We analysed gene copy number of BCL2 and JUNB in 88 DNA samples from 80 patients with ...

      Known for Primary Cutaneous | Expression Bcl2 | Situ Hybridization | Cell Lymphoma | Mf Cases
      KOL-Index: 15394

      Previous cytogenetic studies of primary cutaneous T-cell lymphoma (CTCL) were based on limited numbers of patients and seldom showed consistent nonrandom chromosomal abnormalities. In this study, 54 tumor DNA samples from patients with CTCL were analyzed for loss of heterozygosity on 10q. Allelic loss was identified in 10 samples, all of which were from the 44 patients with mycosis fungoides (10/44 patients; 23%). Of the patients with allelic loss, 3 were among the 29 patients with ...

      Known for Microsatellite Instability | Cell Lymphoma | Patients Mycosis Fungoides | Loss Heterozygosity | Tumor Suppressor
      KOL-Index: 14520

      Allelotyping studies have been extensively used in a wide variety of malignancies to define chromosomal regions of allelic loss and sites of putative tumor suppressor genes; however, until now this technique has not been used in cutaneous lymphoma. We have analyzed 51 samples from patients with mycosis fungoides and 15 with Sézary syndrome using methods to detect loss of heterozygosity. Micro satellite markers were selected on 15 chromosomal arms because of their proximity to either ...

      Known for Mycosis Fungoides | Sézary Syndrome | Allelic Loss | Human Pair | 10q 17p
      KOL-Index: 13773

      There are few data on the molecular pathogenesis of cutaneous T cell lymphomas. A recent allelotyping study by our group identified frequent allelic loss on 9p, 10q, and 17p including losses on 9p21 in 16% of patients with mycosis fungoides and 46% with Sezary syndrome. The P15 and P16 genes are intricately linked on 9p21 and can be inactivated in melanoma and non-Hodgkin's lymphoma. We have therefore studied 76 patients with either mycosis fungoides or Sezary syndrome for abnormalities ...

      Known for Sezary Syndrome | Mycosis Fungoides | P16 Gene | Abnormalities P15 | Dna Methylation
      KOL-Index: 13213

      Primary cutaneous lymphomas (PCLs) represent a heterogeneous group of extranodal T- and B-cell malignancies. The underlying molecular pathogenesis of this malignancy remains unclear. This study aimed to characterize oncogene abnormalities in PCLs. Using genomic microarray, we detected oncogene copy number gains of RAF1 (3p25), CTSB (8p22), PAK1 (11q13), and JUNB (19p13) in 5 of 7 cases of mycosis fungoides (MF)/Sezary syndrome (SS) (71%), gains of FGFR1 (8p11), PTPN (20q13), and BCR ...

      Known for Cell Lymphoma | Primary Cutaneous | Cases Junb | Mycosis Fungoides | Polymerase Chain
      KOL-Index: 13022

      BACKGROUND: Cutaneous lymphomas expressing a cytotoxic or natural killer (NK) cell phenotype represent a group of lymphoproliferative disorders for which there is currently much confusion and little consensus regarding the best nomenclature and classification.

      METHODS: This study analyzes 48 cases of primary cutaneous lymphoma expressing cytotoxic proteins and/or the NK cell marker, CD56. These cases were collected for a workshop of the European Organization for Research and Treatment of ...

      Known for Cutaneous Lymphoma | Natural Killer | Cytotoxic Proteins | Nk Cell | Nasal Type
      KOL-Index: 12497

      PURPOSE: Sentinel node biopsy (SNB) is a surgical technique for detecting micrometastatic disease in the regional draining nodes. 2-fluorine-18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scanning is an imaging technique that can detect clinically undetectable metastases. This prospective study was undertaken to compare the sensitivity of FDG-PET scanning with SNB in the detection of micromatastatic malignant melanoma.

      PATIENTS AND METHODS: Fifty consecutive patients ...

      Known for Node Biopsy | Emission Tomography | Patients Primary Melanoma | Pet Scanning | Metastatic Disease
      KOL-Index: 12448

      BACKGROUND: The t(14;18)(q32;q21) chromosomal translocation is found in the majority of nodal follicular lymphomas and in a lower percentage of systemic high-grade diffuse large B-cell lymphomas. The translocation results in the juxtaposition of the bcl-2 gene on chromosome 18 with the immunoglobulin heavy chain joining region on chromosome 14. Bcl-2 protein prevents apoptosis and the translocation leads to overexpression of a functionally normal Bcl-2 protein that prevents apoptosis of ...

      Known for Chromosomal Translocation | Primary Cutaneous | Cell Lymphoma | Skin Neoplasms | Sequence Analysis
      KOL-Index: 11562

      In a significant proportion of melanoma patients, CTL specific for the melan-A(26/7-35) epitope can be detected in peripheral blood using HLA-A2/peptide tetramers. However, the functional capacity of these CTL has been controversial, since although they prove to be effective killers after in vitro expansion, in some patients they have blunted activation responses ex vivo. We used phenotypic markers to characterize melan-A tetramer(+) cells in both normal individuals and melanoma ...

      Known for Melanoma Patients | Specific Ctl | Cytotoxic Tumor Cells | Immune Response | Peripheral Blood
      KOL-Index: 11439

      T cell receptor gene analysis is a sensitive method for assessment of peripheral blood involvement in mycosis fungoides. This study uses polymerase chain reaction/single-strand conformational polymorphism (PCR/SSCP) analysis of the T cell receptor gamma gene and relates the results to skin stage and outcome in mycosis fungoides. Seventy-five peripheral blood samples from 66 patients were obtained from 1990 onwards and subjected to PCR/SSCP. Both Southern blot analysis and PCR/SSCP ...

      Known for Peripheral Blood | Mycosis Fungoides | Cell Clone | Independent Prognostic | Southern Blot Analysis
      KOL-Index: 11439

      Primary cutaneous B cell lymphomas represent a distinct group of lymphoproliferative disorders that can be distinguished from systemic lymphoma by their good response to local treatment and favorable prognosis. In systemic B cell lymphoma, inactivation of p15(INK4b) and p16(INK4a) is frequently observed and may be associated with a poor prognosis. There have been no comprehensive studies in primary cutaneous B cell lymphomas, however. Mechanisms of p15/p16 inactivation include loss of ...

      Known for Cell Lymphoma | Tumor Suppressor | P15ink4b P16ink4a | Primary Cutaneous | P16 Gene
      KOL-Index: 11413

      BACKGROUND: A small proportion of patients with chronic myeloproliferative diseases have constitutive activation of the gene for platelet-derived growth factor receptor beta (PDGFRB), which encodes a receptor tyrosine kinase. The gene is located on chromosome 5q33, and the activation is usually caused by a t(5;12)(q33;p13) translocation associated with an ETV6-PDGFRB fusion gene. The tyrosine kinase inhibitor imatinib mesylate specifically inhibits ABL, PDGFR, and KIT kinases and has ...

      Known for Imatinib Mesylate | Chronic Myeloproliferative | Derived Growth | Situ Hybridization | Pyrimidines Receptor
      KOL-Index: 10696

      BACKGROUND: Data on genome-wide surveys for chromosome aberrations in primary cutaneous T-cell lymphoma (CTCL) are limited.

      OBJECTIVE: To investigate genetic aberrations in CTCL.

      METHODS: We analysed 18 cases of Sézary syndrome (SS) and 16 cases of mycosis fungoides (MF) by comparative genomic hybridization (CGH) analysis, and correlated findings with the results of additional conventional cytogenetics, fluorescent in situ hybridization (FISH) and allelotyping studies.

      RESULTS: CGH ...

      Known for Sézary Syndrome | Mycosis Fungoides | Situ Hybridization | Chromosome Aberrations | Fluorescence Loss
      KOL-Index: 10689

      BACKGROUND: Some lymphomas express natural killer (NK)-cell markers such as the neural cell adhesion molecule, which is recognized by the CD56 antibody. These lymphomas may present in the skin, but do not represent a homogeneous group. The new World Health Organization classification of lymphoma/leukaemia recognizes several types of NK/T-cell neoplasm, including blastic NK-cell lymphoma, which characteristically presents with cutaneous lesions.

      OBJECTIVES: To describe the clinical, ...

      Known for Natural Killer | Nasal Type | Cell Lymphoma | Disseminated Disease | Cutaneous Lesions
      KOL-Index: 10380

      Fusion genes derived from the platelet-derived growth factor receptor beta (PDGFRB) or alpha (PDGFRA) play an important role in the pathogenesis of BCR-ABL-negative chronic myeloproliferative disorders (CMPDs). These fusion genes encode constitutively activated receptor tyrosine kinases that can be inhibited by imatinib. Twelve patients with BCR-ABL-negative CMPDs and reciprocal translocations involving PDGFRB received imatinib for a median of 47 months (range, 0.1-60 months). Eleven had ...

      Known for Myeloproliferative Disorders | Pdgfrb Fusion | Negative Chronic | Imatinib Patients | Bcr Abl

      Key People For Mycosis Fungoides

      Top KOLs in the world
      #1
      Rein Willemze
      mycosis fungoides cell lymphoma sézary syndrome
      #2
      Eric C Vonderheid
      mycosis fungoides sézary syndrome cell lymphoma
      #3
      Sean J Whittaker
      mycosis fungoides sézary syndrome cell lymphoma
      #4
      Lorenzo Cerroni
      mycosis fungoides cell lymphoma skin neoplasms
      #5
      Günter Burg
      cutaneous lymphomas mycosis fungoides cell lymphoma
      #6
      Robert Martin Knobler
      extracorporeal photopheresis host disease mycosis fungoides

      Robin J Russell‐Jones:Expert Impact

      Concepts for whichRobin J Russell‐Joneshas direct influence:Mycosis fungoides,  Sézary syndrome,  Cell lymphoma,  Extracorporeal photopheresis,  Livedoid vasculitis,  Cutaneous lymphoma,  Peripheral blood,  Cutaneous lymphomas.

      Robin J Russell‐Jones:KOL impact

      Concepts related to the work of other authors for whichfor which Robin J Russell‐Jones has influence:Mycosis fungoides,  Cell lymphoma,  Sézary syndrome,  Extracorporeal photopheresis,  Host disease,  Primary cutaneous,  Skin neoplasms.


       

      Tools

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile


      St John's Institute of Dermatology London UK | Melanoma Group, Skin Tumour Unit, St John’s Institute of Dermatology, St Thomas’ Hospital, London, UK | St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Trust, London SE1 7EH, U.K. | St John’

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.